Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
Active, not recruiting · Phase 2 · NCT02007044
Conditions: Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma
At a glance
- Research payments reported, 2025
- $3.7M
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 66
About the trial
- Sponsor
- M.D. Anderson Cancer Center (with National Cancer Institute (NCI))
- Tested
- Ibrutinib (drug), Quality-of-Life Assessment (other), Questionnaire Administration (other), Rituximab (biological)
- Dates
- Started 2013-12-06; completion 2028-06-30
- Results posted
- Not yet
This phase II trial studies ibrutinib with or without rituximab in treating patients with chronic lymphocytic leukemia that has come back after treatment. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as rituximab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether ibrutinib is more effective with or without rituximab in treating chronic lymphocytic leukemia.
From ClinicalTrials.gov, last updated 2026-06-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $3.7M in research payments for this study in 2025 (3 payments).
Products named: Imbruvica
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Ut MD Anderson Cancer Center $3.7M
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.